Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
Open Access
- 23 November 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Allergy and Asthma Reports
- Vol. 11 (1), 12-20
- https://doi.org/10.1007/s11882-010-0160-9
Abstract
Cryopyrin-associated periodic syndrome (CAPS) is a rare hereditary inflammatory disorder encompassing a continuum of three phenotypes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. Distinguishing features include cutaneous, neurological, ophthalmologic, and rheumatologic manifestations. CAPS results from a gain-of-function mutation of the NLRP3 gene coding for cryopyrin, which forms intracellular protein complexes known as inflammasomes. Defects of the inflammasomes lead to overproduction of interleukin-1, resulting in inflammatory symptoms seen in CAPS. Diagnosis is often delayed and requires a thorough review of clinical symptoms. Remarkable advances in our understanding of the genetics and the molecular pathway that is responsible for the clinical phenotype of CAPS has led to the development of effective treatments. It also has become clear that the NLRP3 inflammasome plays a critical role in innate immune defense and therefore has wider implications for other inflammatory disease states.Keywords
This publication has 82 references indexed in Scilit:
- Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretionProceedings of the National Academy of Sciences of the United States of America, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signalsClinical Immunology, 2010
- Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnessesJournal of Allergy and Clinical Immunology, 2009
- The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnnals Of The Rheumatic Diseases, 2009
- An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor AntagonistNew England Journal of Medicine, 2009
- An Autoinflammatory Disease Due to Homozygous Deletion of theIL1RNLocusNew England Journal of Medicine, 2009
- In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromesThe Journal of Experimental Medicine, 2009
- A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndromeArthritis & Rheumatism, 2008
- A pilot study of IL-1 inhibition by anakinra in acute goutArthritis Research & Therapy, 2007